Cagrilintide

Cagrilintide — A Promising Agent in the Fight Against Obesity and Metabolic Disorders

Obesity and associated metabolic disorders represent a serious public health problem. In search of effective treatment methods, scientists and pharmacists are constantly exploring new substances and approaches. One such promising agent is cagrilintide, a synthetic analogue of amylin — a hormone produced by the pancreas.

What is amylin and how does it work?

Amylin is a hormone that is produced by the beta cells of the pancreas simultaneously with insulin. It performs several important functions:

• Regulates appetite by reducing hunger and promoting satiety.

• Slows gastric emptying, which contributes to a longer feeling of fullness.

• Regulates energy balance, contributing to weight loss and improved metabolism.

Properties and Mechanism of Action of Cagri

The main effects are realized through influence on satiety centers and metabolism:

• Slows gastric emptying → food lingers longer, stomach walls stretch, the satiety signal intensifies.

• Activates amylin receptors in the area postrema and nucleus tractus solitarius, as well as hypothalamic structures, which reduces hunger and cravings for "reward" food (via dopaminergic, opioid, and cannabinoid systems).

• Suppresses postprandial glucagon secretion, improving glycemic control, and potentiates the action of insulin and leptin, increasing sensitivity of leptin receptors and STAT3 signaling.

• Decreases calorie intake and increases energy expenditure, leading to sustained body mass reduction of 8–17% during monotherapy, more so in combination with GLP‑1 agonists.

Refresh Protocol "Double Power"

2 times per week Cagri 2.4 mg SC

IV drips (AOD + L-carnitine) + protein 2g/kg

Monitoring: Waist CT, DEXA every 8 weeks

Goal: -25% weight within a year

• Cagrilintide belongs to the next generation of anti-obesity peptides and is actively discussed in professional communities as a candidate for the standard of combined therapy alongside GLP‑1/dual/triple agonists.

• In reviews for physicians and audiences, it is positioned as one of the most promising tools for patients who have:

• insufficient effect from single GLP‑1 therapy;

• pronounced emotional and "reward-based" component of overeating.

Cagrilintide represents a promising agent for the treatment of obesity and metabolic disorders. Its efficacy and safety make it an attractive option for patients suffering from these problems.